IE83591B1 - Tilidene salts - Google Patents
Tilidene saltsInfo
- Publication number
- IE83591B1 IE83591B1 IE1999/0301A IE990301A IE83591B1 IE 83591 B1 IE83591 B1 IE 83591B1 IE 1999/0301 A IE1999/0301 A IE 1999/0301A IE 990301 A IE990301 A IE 990301A IE 83591 B1 IE83591 B1 IE 83591B1
- Authority
- IE
- Ireland
- Prior art keywords
- tilidine
- salicylate
- acetylsalicylate
- pharmaceutical composition
- preparation
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 18
- 239000011780 sodium chloride Substances 0.000 title claims description 18
- 229960001402 tilidine Drugs 0.000 claims abstract description 72
- WDEFBBTXULIOBB-WBVHZDCISA-N Tilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims abstract description 63
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 32
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims abstract description 24
- 229960001860 salicylate Drugs 0.000 claims abstract description 24
- 229940068372 Acetyl salicylate Drugs 0.000 claims abstract description 23
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 14
- WHYVWQHDUOALSV-UMJMSJQKSA-N ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C.C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WHYVWQHDUOALSV-UMJMSJQKSA-N 0.000 claims abstract description 13
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 7
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical group CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000000875 corresponding Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 229960001502 Tilidine Hydrochloride Drugs 0.000 claims 1
- 239000002585 base Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic Effects 0.000 description 2
- 230000001754 anti-pyretic Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- ZGZWRSASDRZAIL-UHFFFAOYSA-N 2-acetyloxybenzoic acid;azane Chemical class N.CC(=O)OC1=CC=CC=C1C(O)=O ZGZWRSASDRZAIL-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 229940063284 Ammonium salicylate Drugs 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BOFZOTMTKBQRAB-UHFFFAOYSA-N azanium;2-carboxyphenolate Chemical compound N.OC(=O)C1=CC=CC=C1O BOFZOTMTKBQRAB-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Abstract
Abstract Tilidine Acetylsalicylate and Tilidine Salicylate are formed by reacting Tilidine Hydrochloride Hemihydrate with Acetylsalicylic or Salicylic acid respectively.
Description
Tilidine Salts
Introduction
The invention relates to novel salts of Tilidine, processes for their preparation and
their use in pharmaceutical products.
(i)-Ethyl-rrcms—2-(dimethylamino)-1«phenyl-3—cyclohexene—l—carboxylate
(Tilidine) is a pharmaceutically active substance with strong analgesic properties.
Trans-Tilidine Base (1) is known to be a compound with a very low melting point
(Pharm. Ind. 40(6), 657-664 [1978]; Cienc. Ind. Farm. 8(1). 4-11 [1976]). This
creates problems for the manufacture of final pharmaceutical products.
Therefore, Tilidine is generally used in pharmaceuticals in the form of
Hydrochloride Hemihydrate, a more stable compound than Tilidine base itself. As
the Hydrochloride Hemihydrate is very soluble in water it is suitable for the
preparation of solutions which can be administered for fast pain relief. Certain
types of soft capsules can also be manufactured using Tilidine Hydrochloride
Hemihydrate as an active ingredient. However, the Hydrochloride Hemihydrate
is not suitable for “solid formulations” required for the production of tablets.
Furthermore it seems to be unsuitable for the manufacture of Tilidine containing
products with a retard profile.
Salts other than Tilidine Hydrochloride Hemihydrate are described in WO-A-
94/ 10129. The compound disclosed is Tilidine Dihydrogen Orthophosphate,
which is said to be stable and therefore suitable for the preparation of solid
pharmaceutical formulations such as tablets or dragees. However, the process for
the preparation of Tilidine Dihydrogen Orthophosphate appears to be critical and
complicated.
There is therefore a need for a new chemical entity based on Tilidine which is
stable, easily producible in high quality and good yields and which can be
formulated to provide a range of different delivery routes.
This invention is directed towards providing such a new entity.
Statements of Invention
According to the invention there is provided an acid base salt adduct of Tilidine
formed by reacting Tilidine with acetylsalicylic acid or salicylic acid as their
corresponding salts.
Preferably the Tilidine is introduced in the form of Tilidine Hydrochloride
Hemihydrate.
One aspect of the invention provides Tilidine Acetylsalicylate.
Yet another aspect of the invention provides Tilidine Salicylate.
In one embodiment the invention provides a process for the preparation of
Tilidine Acetylsalicylate comprising:-
reacting Tilidine Hydrochloride Hemihydrate with an Acetylsalicylic Acid
salt and isolating the desired salt.
In another embodiment the invention provides a process for the preparation of
Tilidine Salicylate comprising:—
reacting Tilidine Hydrochloride Hemihydrate with a Salicylic Acid salt and
isolating the desired salt.
The reaction is preferably carried out in the presence of a base such as an amine
base for example ammonia, triethylamine, Hiinigs base or hydroxides such as
alkali hydroxides.
Most preferably the reaction is carried out in an appropriate solvent, typically
MIBK, MEK, acetone, THF, or n—butanol. However other solvents may be used.
Preferably the reaction temperature is from 0 to 80°C, most preferably from 0 to
°C.
The invention further provides a pharmaceutical composition containing Tilidine
Acetylsalicylate as an active ingredient.
The invention further provides a pharmaceutical composition containing Tilidine
Salicylate as an active ingredient.
The composition may be in a solid form. Typically the composition is in the form
of a tablet, dragee, capsule, suppository, granulate or plaster.
The composition may be used as a retard formulation for sustained release or for
dual action applications.
The invention will be more clearly understood from the following description
thereof given by way of example only.
Description of the Invention
It has been found that Tilidine Acetylsalicylate and Tilidine Salicylate can be
obtained via a simple process. The salts are very stable, show unusual solubility
and pH properties and are suitable for solid formulations.
Furthermore Tilidine Acetylsalicylate and Tilidine Salicylate can be used in
plasters for percutaneous applications in the form of a transdermal patch and for
dual action applications.
According to the literature (W O-A—94/ 10129) Tilidine salts are difficult to
crystallise. Surprisingly therefore we have found that Tilidine Acetylsalicylate and
Tilidine Salicylate can be crystallised as l:l-adducts by reacting Tilidine
Hydrochloride Hemihydrate and salts of Acetylsalicylic Acid or Salicylic Acid, for
example in organic or organic/ aqueous or aqueous media. Tilidine
Acetylsalicylate and Tilidine Salicylate can be isolated as a white to off-white,
odourless powder in high yield. Both salts show a pH value of 5-6 (~1% aqueous
solution) which is, compared to the Hydrochloride Hemihydrate and Dihydrogen
Orthophosphate, more basic, almost in the neutral range. It was found that the
Acetylsalicylate and the Salicylate are very stable over a long period of time.
Furthermore the Acetylsalicylate and the Salicylate are non-hygroscopic in
contrast to known Tilidine salts such as Tilidine Hydrochloride Hemihydrate and
Dihydrogen Orthophosphate.
As Tilidine Acetylsalicylate and Tilidine Salicylate are very stable and non-
hygroscopic they are very suitable for the manufacture of granulates which are
readily convertible into tablets, dragees or pills. A delayed action of the active
compound Tilidine may be obtained by incorporation in a suitable retard
formulation.
Due to poor water solubility the compounds may be used for the manufacture of
plasters/ patches for percutaneous applications with a delayed and slow release of
the active ingredients.
In preparing such compositions any of the various adjuvant or excipient materials
customarily employed in the art may be used. These adjuvants or excipients
include, for example, inert substances such as water, gelatine, lactose, vegetable
oil as well as many of the other compatible materials conventionally used in the
preparation of medicaments.
As Tilidine Acetylsalicylate and Tilidine Salicylate are combinations of two active
compounds either may be used for dual action applications.
Tilidine is known to be a highly potent analgesic which is used for the treatment
of severe pain. Salicylic acid and Acetylsalicylic acid can be used as a mild
analgesic with an additional antipyretic and antiphlogistic profile. Moreover in
particular Acetylsalicylic acid is known for its antithrombotic activity. Therefore it
can be anticipated that the salts Tilidine Acetylsalicylate and Tilidine Salicylate
respectively show an advanced pharmacological profile over Tilidine
Hydrochloride Hemihydrate. The salts are therefore useful if a tandem therapy is
required in the sense of additional antipyretic, antithrombotic or antiphlogistic
effectiveness.
The process for the preparation of Tilidine Acetylsalicylate and Tilidine Salicylate
is extremely simple and efficient. The product is isolated in a simple procedure at
high yields, greater than 50% and at a very high level of purity, greater than 99%.
Reaction Scheme
G) NHRTRZR3
(D O
H C-N .H CH 9
v are/“ 3 do
_j> \
Q °
0)\CH3
Tilidine Acetylsalicylate
s O9 G) NHFVRQR3
+
OH I
Tilidine Salicylate
R1, R2 and R3 are hydrogen or C1—C4 alkyl groups. In addition to the ammonium
acetylsalicylates and salicylates the corresponding earth alkali salts may also be
utilised in the process. Preferred salts, in these cases, are sodium or potassium
analogues.
Example 1
Preparation of Tilidine Acetylsalicylate
.2g (0.056 mol) of Acetylsalicylic Acid were dissolved in 100-150 ml of a
suitable organic solvent such as methanol, ethanol, acetone, THF or mixtures
thereof. The solution was treated with one equivalent of base. The base may
typically be triethylamine, Hunigs base or ammonia. The mixture was agitated
and l8.lg (0.056 mol) of Tilidine Hydrochloride Hemihydrate were added.
Agitation was continued for 0.5-2 hours, preferably at room temperature. The by-
product formed was removed by filtration. The solvent was removed from the
mother liquor by distillation, preferably under vacuum conditions providing the
crude product in almost quantitative yield. The product may be purified by
crystallisation from a suitable solvent such as ether, petroleum ether or mixtures
thereof. Typically a yield of >50% of the purified material is obtained.
FT-IR (KBr): v[cm“] = 2978, 1727, 1588, 1485, 1458, 1371, 1321, 1237, 1200,
1146, 729, 704.
Stability
Tilidine Acetylsalicylate was found to be stable when stored over a long period of
time under standard conditions. No critical change in purity was observed and no
significant amounts of degradation product was detected.
Example 2
Preparation of Tilidine Salicylate
Aqueous ammonia was added to 43.4g (0.31 mol) of Salicylic Acid until complete
dissolution was obtained. The excess of ammonia can then be removed under
vacuum. 100g (0.31 mol) of Tilidine Hydrochloride Hemihydrate were dissolved
in 200-250 ml of water and mixed with the previously prepared ammonium
salicylate. The mixture was stirred at room temperature for 0.5-l hour. The
product was extracted from the aqueous phase with a suitable solvent such as
MIBK or CHCI3. After removing the organic solvent the product was crystallised
from the obtained oil by treatment with MIBK/ Petroleum Ether.
A typical yield of 90g corresponding approximately to 70% is obtained with a
melting point of 997°C.
IH-NMR (CDCI3, 60 MHz): <3 = 1.05 (t, 3H,CH2CH3); 2.25-2.60 (m, 10H,
N(CH3)2, CHZCHZ); 4.05 (q, 2H,CH2CH3); 4.45 (db,,lH, NCH); 5.95-6.15 (m, 2H,
CH=CH), 6.75- 7.85, (m, 10H, aryl-H, NH); 12.0 (s, 1H, OH).
FT-IR (KBr): v[cm‘1] = 2977, 2476, 1728, 1624, 1587, 1485, 1459, 1371, 1322,
1294, 1237, 1147, 854, 770, 729, 704.
Stability
Tilidine Salicylate was found to be stable when stored over a long period of time
under standard conditions. No critical change in purity was observed and no
significant amounts of degradation product was detected.
Example 3
Retard Formulation of Tilidine Salicylate
l070g Tilidine Salicylate prepared as in example 2 was added to 70.4g Naloxon
Hydrochloride Dihydrate, 740g lactose and 700g hydrated Castor oil, slowly
stirred and heated up to a temperature of 50—85°C. The mixture was filtered
through a filter with a pore size of 2.5mm. After cooling to room temperature, the
mixture was further filtered through a filter with a pore size of 1 mm. 273.6g of
ammonia methyl acrylate co-polymer, 32 g magesium stearate and 24 g silicon
dioxide were added to the mixture. The resultant mixture was then compressed
into tablet form. Retard formulations of Tilidine Acetylsalicylate may be prepared
using an analogous protocol.
The invention is not limited to the embodiments hereinbefore described which
may be varied in detail.
Claims (1)
- Claims An acid base salt adduct of Tilidine formed by reacting Tilidine with acetylsalicylic acid or salicylic acid as their corresponding salts. An acid base salt adduct as claimed in claim 1 wherein the Tilidine is introduced in the form of Tilidine Hydrochloride Hemihydrate. Tilidine Acetylsalicylate. Tilidine Salicylate. A process for the preparation of Tilidine Acetylsalicylate comprising:- Tilidine Hydrochloride with an Acetylsalicylic Acid salt and isolating the desired salt. reacting Hemihydrate A process for the preparation of Tilidine Salicylate comprising:- reacting Tilidine Hydrochloride Hemihydrate with a Salicylic Acid salt and isolating the desired salt. A process as claimed in claim 5 or 6 wherein the reaction is carried out in the presence of a base such as ammonia, Hiinigs base or triethylamine. A process as claimed in any of claims 5 to 7 wherein the reaction is carried out in an appropriate solvent. A process as claimed in any of claims 5 to 8 wherein the process carried out at a temperature of from 0 to 80°C. 10. A process as claimed in claim 9 wherein the process is carried out at a temperature of from O to 30°C. 11. A process as claimed in any of claims 8 to 10 wherein the solvent is MIBK. 12. A process for the preparation of Tilidine Acetylsalicylate substantially as herein before described with reference to the example. 13. A process for the preparation of Tilidine Salicylate substantially as hereinbefore described with reference to the example. 14. Tilidine Acetylsalicylate whenever prepared by a process as claimed in any ofclaims 5 or 7 to 12. 15. Tilidine Salicylate whenever prepared by a process as claimed in any of claims 6 to 11 or 13. 16. A pharmaceutical composition containing Tilidine Acetylsalicylate as an active ingredient. 17. A pharmaceutical composition containing Tilidine Salicylate as an active ingredient. l8. A pharmaceutical composition as claimed in claim 16 or 17 in a solid form. 19. A pharmaceutical composition as claimed in any of claims 16 to 18 which Qgmiilated to provide a retard formulation. A pharmaceutical composition as claimed in any of claims 16 to 19 which is in a form for percutaneous application. A pharmaceutical composition as claimed in any of claims 16 to 20 which is in the form of a transdermal patch. A pharmaceutical composition substantially as hereinbefore described with reference to the examples.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE1999/0301A IE83591B1 (en) | 1999-04-09 | Tilidene salts |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IEIRELAND14/07/19981998/0564 | |||
| IE980564 | 1998-07-14 | ||
| IE1999/0301A IE83591B1 (en) | 1999-04-09 | Tilidene salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IE990301A1 IE990301A1 (en) | 2000-03-08 |
| IE19990301A1 IE19990301A1 (en) | 2000-03-08 |
| IE83591B1 true IE83591B1 (en) | 2004-09-22 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1709053B1 (en) | Stable salts of olanzapine | |
| SK125993A3 (en) | Therapeutic agent | |
| WO2010013048A1 (en) | Polymorphic form of rasagiline mesylate | |
| KR100830002B1 (en) | Inorganic Acid Salts of Sibutramine | |
| KR20170061616A (en) | New salt of fimasartan | |
| US6939856B2 (en) | Method for preparing dexchlor tannate | |
| US6881744B2 (en) | Carbinoxamine tannate | |
| MXPA02000033A (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2, 2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists. | |
| IE83591B1 (en) | Tilidene salts | |
| WO2013160354A1 (en) | Crystalline forms of saxagliptin | |
| CA2164296C (en) | Heterocyclic chemistry | |
| AU744888B2 (en) | Tilidine mesylate, processes for its preparation and pharmaceutical composition thereof | |
| IE19990301A1 (en) | Tilidene salts | |
| IE990301A1 (en) | Tilidene salts | |
| JPWO2002083633A1 (en) | Splatast tosilate crystal | |
| JP3830816B2 (en) | Crystalline polymorphs of azabicyclo (2.2.2) octane-3-amine citrate and pharmaceutical compositions thereof | |
| US6455727B1 (en) | Process for preparing carbetapentane tannate | |
| JP5702778B2 (en) | Crystalline Form I Rosuvastatin Zinc Salt | |
| JP5530369B2 (en) | New crystal form | |
| SK17342001A3 (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3- yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists | |
| US7001886B2 (en) | Hot melt method for preparing diphenhydramine tannate | |
| IE990300A1 (en) | Tilidine Embonate | |
| IE83619B1 (en) | Tilidine mesylate | |
| WO2011099942A1 (en) | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy | |
| KR20200068667A (en) | Stemospironine in solid form and salts thereof |